Actavis' planned acquisition of Allergan has been completed, following approval...

Actavis' planned acquisition of Allergan has been completed, following approval by the shareholders of both companies. The transaction, which is worth about $70.5 billion, creates one of the ten largest pharmaceutical companies in the world, with combined revenues expected to reach more than $23 billion in 2015. As previously reported, ...

You need to register to continue reading this article

Already subscribe to Eyewear intelligence? Sign in here

Register to continue reading

By registering today you will have access to:

  • 3 industry news articles per month

For full access and to receive in-depth news, analysis and more, become a member today

For more content and resources become a member? View our membership packages.